Yicura BioMed, a clinical-stage immunotherapy company based in Hong Kong Science Park, completed the first closing of its Series B financing. Gobi Partners led the round. Strategic investors from Wuxi and institutional investors from Hong Kong also participated.
Use of proceeds
The new capital will advance ICVAX, the company’s HIV vaccine program. It will also accelerate cancer immunotherapy work across vaccine and antibody platforms. The funding supports both clinical and pipeline development.
Company background
Yicura develops medicines for infectious diseases, cancers, and inflammatory diseases. The company operates from Hong Kong Science Park. Dr. Xia Jin is co-founder and CEO.
Clinical progress
ICVAX has completed a randomized, placebo-controlled Phase I trial. The NMPA-approved study involved people living with HIV on antiretroviral therapy. Results showed favorable safety and immunogenicity.
Yicura is advancing ICVAX to a Phase II clinical trial. The study will assess efficacy for more durable immune control of HIV. The program’s target path is a functional cure.